Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

ing requirements with respect to Fanapt™.  Vanda also plans to continue the clinical, regulatory and commercial evaluation of tasimelteon.  Although Vanda incurred transaction-related costs of approximately $6.0 million in the fourth quarter of 2009, which included financial advisor fees, consulting fees, legal expenses and employee bonuses, and $2.0 million in Fanapt™ inventory costs, Vanda's fixed overhead costs are expected to be approximately $10.0 million to $12.0 million annually.  Vanda will recognize revenue of $26.8 million in 2010 for the amortization of the deferred upfront payment received from Novartis.  The forecasted royalty revenue and sales milestones based on sales of Fanapt™ by Novartis can not be determined at this time.  Vanda expects to receive approximately $7.7 million from Novartis for Fanapt™ inventory, of which $2.0 million was recorded as a receivable at year-end.  

Vanda is currently working with its tax advisors to determine its tax liability relating to the receipt of the $200.0 million upfront payment from Novartis in late 2009.  Generally, under the Internal Revenue Code, an accrual basis taxpayer is required to include in taxable income certain cash payments in the year received.  Revenue Procedure 2004-34, however, allows taxpayers a limited deferral beyond the taxable year of receipt for certain advance payments.  For federal income tax purposes, Vanda may avail itself of the provisions of this Revenue Procedure to defer recognition of income on the upfront payment from Novartis.  As a result, only a portion of the $200.0 million upfront payment from Novartis that was received in 2009 is expected to be include
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
(Date:12/19/2014)... iLab Solutions, the global leader in core ... as the new Director of Institutional Implementations and Sarah ... two new leadership positions were created to support iLab’s ... iLab continues to meet the needs of its growing ... has been deployed at over 450 core facilities across ...
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... 19 Alexandria Real Estate Equities, Inc. (NYSE: ... offering of 7,000,000 shares of common stock at a price ... of 4,500,000 shares. Merrill Lynch & Co., Citi and ... & Woods and Scotia Capital acted as co-managers in connection ...
... - EPA Exercises Option to Extend Contract with Caliper ... (Nasdaq: CALP ), a leading provider of ... research, today announced that the United States Environmental Protection ... generated by Caliper Discovery Alliances and Services (CDAS) under ...
... Administration, Bioavailability, Safety, and Efficacy of TreatmentsMOUNTAIN ... its recent analysis of the ocular drug ... Pharma with the 2009 North American Frost ... Advancement of the Year, for its two ...
Cached Biology Technology:Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock 2Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock 3EPA Presents Initial Results from Caliper Life Sciences' ToxCast Screening Effort 2EPA Presents Initial Results from Caliper Life Sciences' ToxCast Screening Effort 3EPA Presents Initial Results from Caliper Life Sciences' ToxCast Screening Effort 4Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies 2Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies 3Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies 4
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced ... the APAC Region 2015-2019"  report to their offering. ... this market is advances in technology. With continuous ... biometric solutions to the latest standard that meets ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... has published the genome sequence of the rhesus macaque ... genomes. Published April 13 in a special section of ... primate species share about 93 percent of their DNA, ... In its paper, the Rhesus Macaque Genome Sequence and ...
... at the University of Chicago have found an unsuspected link ... and triglycerides in the blood) in mice. The finding could ... disease by lowering elevated lipid levels. , In ... by James C. Lo, an MD, PhD student, in the ...
... asbestos exposure ?have a higher survival rate when treated with ... finds. , Mesothelioma, a rare but aggressive form of cancer ... abdomen, is associated with exposure to asbestos. There is no ... and cisplatin ?along with the vitamin supplements folic acid and ...
Cached Biology News:Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 3Link found between immune system and high plasma lipid levels 2Chemo combination improves survival in asbestos-related cancer 2Chemo combination improves survival in asbestos-related cancer 3
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
...
... Ambions MAXIscript In Vitro Transcription Kits synthesize ... x 10 9 cpm/g. High specific ... ribonuclease protection assays, in situ hybridization, and ... used for the synthesis of modest amounts ...
Biology Products: